Jazz Pharmaceuticals (JAZZ) Tops Q4 EPS by 14c
Tweet
Share
E-mailGet Alerts JAZZ Hot Sheet
Price: $254.90 +2.63%
Financial Fact:
Research and development: 47.8M
Today's EPS Names:
SCWO, HSAI, SYRS, More
Financial Fact:
Research and development: 47.8M
Today's EPS Names:
SCWO, HSAI, SYRS, More
Join SI Premium – FREE
Jazz Pharmaceuticals (NASDAQ: JAZZ) reported Q4 EPS of $2.44, $0.14 better than the analyst estimate of $2.30. Revenue for the quarter came in at $328.1 million versus the consensus estimate of $319.74 million.
For earnings history and earnings-related data on Jazz Pharmaceuticals (JAZZ) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Klarna shares tumble on weak full-year revenue guidance
- Xylem names Andrea van der Berg as CFO, effective Sept. 2026
- DeFi Technologies (DEFT) PT Lowered to $1 at Benchmark Following Q2 Miss
Create E-mail Alert Related Categories
EarningsRelated Entities
EarningsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
